Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROKETAZINE vs TRILAFON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenothiazine neuroleptic with central antidopaminergic and anticholinergic effects; blocks dopamine D2 receptors in the chemoreceptor trigger zone and hypothalamus, producing antiemetic and antipsychotic activity.
Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.
Nausea and vomiting,Antipsychotic (off-label),Sedation (off-label)
Schizophrenia,Schizoaffective disorder,Severe nausea and vomiting (in adults),Bipolar disorder (off-label)
25 mg intramuscularly every 6-8 hours; maximum 100 mg per day.
8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.
Terminal elimination half-life is 15-20 hours in healthy adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is approximately 10–20 hours (mean ~12 hours); supports twice-daily dosing.
Hepatic via CYP2D6 and other cytochrome P450 enzymes.
Extensively metabolized in the liver via glucuronidation, sulfoxidation, side-chain oxidation, and N-dealkylation. CYP2D6 is a major enzyme involved in metabolism; polymorphisms can lead to poor metabolizer status.
Primarily renal excretion of metabolites; less than 1% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 20% of total clearance.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for the majority of elimination.
Approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
90–95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution is 20-30 L/kg, indicating extensive tissue distribution and high lipophilicity.
Approximately 10–15 L/kg; large Vd indicates extensive tissue distribution.
Oral bioavailability is 30-40% due to extensive first-pass metabolism. IM bioavailability is approximately 70%.
Oral: 40–50% (due to first-pass metabolism); IM: 100% (assumed complete absorption).
GFR 30-50 m L/min: reduce dose by 25%; GFR <30 m L/min: reduce dose by 50% and extend interval to every 12 hours.
No dosage adjustment required for GFR 10-50 m L/min; use 50% of normal dose if GFR <10 m L/min.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
0.5-1 mg/kg intramuscularly every 6-8 hours; maximum 50 mg per day for children <12 years.
Not recommended for children under 12 years; for ages 12 and older, 6-12 mg orally 2-3 times daily; maximum 24 mg/day.
Initial dose 12.5 mg intramuscularly; maximum 50 mg per day; monitor for anticholinergic effects and sedation.
Initiate at 4-8 mg orally daily; increase slowly; monitor for QT prolongation, hypotension, and tardive dyskinesia.
Increased risk of death in elderly patients with dementia-related psychosis; not approved for dementia-related psychosis.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Perphenazine is not approved for the treatment of dementia-related psychosis.
May cause QT prolongation, neuroleptic malignant syndrome, tardive dyskinesia, hypotension, and increased risk of falls. Use with caution in patients with cardiovascular disease, seizures, or hepatic impairment.
Extrapyramidal symptoms (including tardive dyskinesia) may occur,Neuroleptic malignant syndrome (NMS) - potentially fatal,QT prolongation and risk of arrhythmias,Orthostatic hypotension,Seizures (lower seizure threshold),Leukopenia, neutropenia, and agranulocytosis,Hematologic toxicity,Hyperprolactinemia,Cognitive and motor impairment,Antiemetic effect may mask signs of toxicity or overdose,Use in elderly with dementia not approved
Hypersensitivity to phenothiazines, severe CNS depression, comatose states, and blood dyscrasias.
Hypersensitivity to perphenazine or any component of the formulation,Comatose states,CNS depression due to alcohol, barbiturates, or other drugs,Subcortical brain damage,Blood dyscrasias,Bone marrow suppression,Severe hypotension,Known QT prolongation or concurrent use with QT-prolonging drugs
Avoid grapefruit juice as it may inhibit metabolism and increase toxicity. Avoid high-tyramine foods (aged cheese, cured meats, fermented products) due to risk of hypertensive crisis if used with MAOIs.
Avoid grapefruit and grapefruit juice as they may increase perphenazine levels. Limit caffeine intake as it may worsen side effects like restlessness. Taking with food may reduce GI upset but avoid high-fat meals which can affect absorption.
PROKETAZINE (prochlorperazine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second/third trimesters: Possible extrapyramidal symptoms and neonatal withdrawal in newborns after maternal use near term. Use only if benefit outweighs risk.
First trimester: Periconceptional use associated with neural tube defects? Limited data; avoid if possible. Second and third trimesters: Risk of extrapyramidal symptoms and/or withdrawal in neonates after late third trimester exposure. Overall, use only if benefit outweighs risk; avoid during organogenesis.
Prochlorperazine is excreted into human breast milk in low amounts. Milk/plasma (M/P) ratio is approximately 1.0. Potential for adverse effects in nursing infants, including sedation and extrapyramidal symptoms. Caution advised; monitor infant for drowsiness and EPS.
Trilafon (perphenazine) is excreted into human milk in small amounts; M/P ratio unknown. Monitor infant for drowsiness, irritability, or movement disorders. Use with caution during breastfeeding.
Pregnancy may increase clearance of prochlorperazine due to expanded blood volume and enhanced hepatic metabolism. Dose adjustments may be needed; consider lower initial doses and titrate based on clinical response. No specific pharmacokinetic data in pregnancy; use minimum effective dose.
No established dose adjustment per se; start at lowest effective dose. Increased plasma volume and metabolism during pregnancy may require dose increases to maintain efficacy; individualize based on response and tolerability.
Monitor for extrapyramidal symptoms, especially in elderly and pediatric patients. Proketazine may cause significant hypotension; avoid rapid IV administration. Contraindicated in patients with bone marrow suppression or severe hepatic impairment.
TRILAFON (perphenazine) is a typical antipsychotic with potent antiemetic properties. Monitor for extrapyramidal symptoms (EPS), especially akathisia and dystonia. Avoid use in patients with CNS depression or bone marrow suppression. May lower seizure threshold; use cautiously in epilepsy. QT prolongation risk requires ECG monitoring. Taper dose when discontinuing to avoid withdrawal dyskinesias.
Avoid alcohol and CNS depressants as they may increase sedation.,Report any involuntary muscle movements or stiffness immediately.,Rise slowly from sitting or lying to prevent dizziness.,May cause dry mouth; use sugar-free gum or candy.,Do not discontinue abruptly without consulting prescriber.
Avoid alcohol and other CNS depressants.,Report any involuntary muscle movements, stiffness, or restlessness immediately.,May cause drowsiness; avoid driving until you know how the medication affects you.,Rise slowly from sitting or lying to prevent dizziness.,Use sun protection as this drug may increase sensitivity to sunlight.,Do not stop taking abruptly without consulting your doctor.,Inform all healthcare providers that you are taking this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROKETAZINE vs TRILAFON, answered by our medical review team.
PROKETAZINE is a Phenothiazine Antipsychotic that works by Phenothiazine neuroleptic with central antidopaminergic and anticholinergic effects; blocks dopamine D2 receptors in the chemoreceptor trigger zone and hypothalamus, producing antiemetic and antipsychotic activity.. TRILAFON is a Phenothiazine Antipsychotic that works by Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROKETAZINE and TRILAFON depend on the specific clinical indication. These are both Phenothiazine Antipsychotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROKETAZINE is: 25 mg intramuscularly every 6-8 hours; maximum 100 mg per day.. The standard adult dose of TRILAFON is: 8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROKETAZINE and TRILAFON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROKETAZINE is classified as Category C. PROKETAZINE (prochlorperazine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second/third t. TRILAFON is classified as Category C. First trimester: Periconceptional use associated with neural tube defects? Limited data; avoid if possible. Second and third trimesters: Risk of extrapyramidal symptoms and/or with. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.